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I  Scope and purpose of this guidance
This evidence-based guidance aims to support the 
planning and implementation of effective programmes 
to prevent and control the transmission of infectious 
diseases in prison settings in the European region. It 
focuses on three high-burden blood-borne viruses (BBV) 
in the prison population, namely hepatitis B virus (HBV), 
hepatitis C virus (HCV) and human immunodeficiency 
virus (HIV) (1). The infections caused by these viruses 
are characterised by the same modes of blood-borne 
transmission and similar prevention and control 
interventions. The key areas covered by this guidance are 
prevention, treatment and care of BBVs in prison settings. 
This guidance is intended for policymakers responsible 
for the planning and delivery of healthcare services in 
the national or sub-national custodial system and all 
professionals responsible for the health and well-being 
of people in prison, including community-based service 
providers and those facilitating continuity of care in 
the community. 
(1)  The BBV guidance presented here is part of a broader project to develop guidance for the 
prevention and control of communicable diseases in prison settings, which covered BBVs, sexually 
transmitted infections and tuberculosis. See the last page.  
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The available scientific evidence, backed up by expert 
opinion, allows for the following key conclusions to be 
made (see also ‘Key conclusions and implementation 
considerations’, page 4):
Prevention
Offer a comprehensive package of preventive measures 
to people in prison that meet the same national 
standards as those recommended for community 
settings.
Evidence shows that also in prison settings, condoms 
and behavioural interventions promote safer sex.
Evidence shows that opioid substitution treatment 
reduces illicit opioid use and risks related to equipment 
sharing and, when continued on release, provides 
protection from death caused by overdose.
Evidence shows that the provision of clean drug injection 
equipment is possible in prison settings and can 
successfully contribute to a comprehensive programme 
to reduce BBV transmission.
HBV vaccination
Offer HBV vaccination to people in prison with unknown 
or negative serology.
Evidence shows that using rapid schedules may result in 
a higher completion rate of the full schedule.  
Testing for viral hepatitis and HIV 
Actively offer BBV testing to all people in prison upon 
admission and throughout the time in prison.
Evidence shows that pro-active provision of BBV testing 
leads to a higher uptake; health promotion and peer 
education have been shown to increase HIV testing 
uptake.
Viral hepatitis and HIV treatment
Offer appropriate treatment to individuals diagnosed 
with HIV, HBV or HCV infection in prison settings, 
in line with the guidelines applied in the community 
and meeting the same provision standards as in the 
community.
Evidence shows that treatment of BBV infections is 
feasible and effective in prison.
Continuity of care
Actively support and ensure continuity of care between 
prison and community.
Evidence shows that release from prison is a key barrier 
to continuity and adherence to drug and infectious 
diseases treatment.
Evidence shows that collaboration and partnership 
between prison and community health-care services 
promote and facilitate uninterrupted care.
Evidence shows that active referral to external services 
improves treatment adherence.
Key conclusions 
I Guidance development
This guidance is based on a series of systematic reviews of 
the scientific literature. Research findings were assessed 
using evidence-based medicine principles, adapted within 
a public health framework and combined with advice from 
a panel of European prison experts. The conclusions listed 
are based on consideration of the strength of evidence 
supplemented by expert opinion. Considerations for 
successful implementation of the interventions in European 
prison settings are also provided.
I Why is this important?
In the 31 EU/EEA countries, more than 590 000 persons are 
held in a custodial facility on any given day, with considerable 
differences between countries’ imprisonment rates — varying 
from 51 per 100 000 general population in the Netherlands to 
over 200 per 100 000 in the Czech Republic, Estonia, Latvia 
and Lithuania (2). Recent reviews of prison studies from EU 
countries found a much higher proportion of individuals in 
prison infected with viral hepatitis as compared to the 
(2) The EU/EEA (European Union and European Economic Area) includes the 
28 EU Member States, Iceland, Liechtenstein and Norway.
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general population, with prison prevalence estimates ranging 
from 0.3 % to 25.2 % for HBV and from 4.3 % to 86.3 % for 
HCV, which is up to 28 and 78 times, respectively, higher than 
estimated prevalence in the general population. Similarly 
for HIV, prison prevalence estimates ranged from 0.2 % to 
15.8 %. People in prison also tend to have multiple complex 
health and social care needs resulting from a mix of specific 
socioeconomic determinants and environmental factors. Poor 
infrastructure, overcrowding, inadequate healthcare facilities 
and delayed diagnosis are recognised additional risk factors 
in prison settings, where much of the burden of blood-borne 
infections is linked to a history of injecting drug use among 
this population.  
Prisons are settings of increased risk for BBV transmission, 
where enhanced and effective prevention and control 
measures are required to protect the health of people 
in detention and staff. At the same time, incarceration 
represents a unique opportunity to address the healthcare 
needs of those people in prison who belong to hard-to-reach 
and medically underserved groups in the community, such as 
people who inject drugs. 
A significant proportion of people in prison have a history of 
drug use, and a strong association has been found between 
prison history and BBV prevalence in people who inject 
drugs. Many serve short sentences or are remanded in 
custody for brief periods before trial. The period surrounding 
arrest and incarceration may be critical in terms of increases 
in risk behaviour and disruption of care. Disruption of opioid 
substitution treatment, especially due to brief periods of 
imprisonment, has been associated with significant increases 
in HCV conversion. Inside prison, the risk of transmission of 
blood-borne infections is increased by behaviours such as 
the sharing of drug-injecting equipment. 
Effective interventions aimed at reducing BBV transmission 
and ensuring entry into treatment and care are available for 
individuals in need in community settings across Europe. 
In accordance with the principle of equivalence of care, 
broader implementation of these interventions should be 
promoted in prison settings, taking into consideration the 
specific conditions and challenges of the prison setting. 
Delivering health protection, prevention and harm reduction 
programmes in prisons will not only benefit the prison 
population but, by targeting ‘high transmission’ networks 
within or linked to prison populations, can also reduce the risk 
of transmission of infectious diseases in the community.
I  Foundational principles for BBV prevention in prison 
Most people held in prison, especially at the early stages of 
their incarceration, are in a state of fragility and vulnerability, 
at times combined with aggressiveness and distrust. The 
reasons for this are complex, but may include general 
psychological problems, substance use, poor health, 
educational deficits and poor social skills. It is advisable to 
take these aspects into consideration during the planning 
and implementation of BBV prevention in prison settings. 
This joint ECDC-EMCDDA guidance defines the following 
seven principles as the foundations for the provision of health 
services aimed at preventing the transmission of BBVs in 
prison settings: consent; confidentiality; communication; 
correct test results; connection to prevention, care and 
treatment; continuity of care post-release; and an overall 
supportive culture within the prison system. These principles 
are essential for the effective implementation of the 
interventions mentioned in the key conclusions of this report.
EQUIVALENCE  
OF CARE
CommunicationConsent
Correct test  
results
Continuity  
of care 
(throughcare, 
aftercare)
Connection  
to care
Supportive  
culture
Confidentiality
Seven foundational principles for the provision of health 
services to prevent transmission of blood-borne viruses in 
prison settings
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I  Key conclusions and implementation considerations 
Medical examination, including a health and drug 
assessment, of all those remanded in custody or entering 
prison after conviction is a widely accepted standard 
of prison healthcare and has been laid down as duty of 
the prison medical practitioner in the European Prison 
Rules. The aim here is to diagnose any physical or mental 
conditions that might be present and take the necessary 
treatment measures, such as ensuring the continuation of 
existing medical treatment.
Reducing BBV transmission through  
combination prevention
The body of scientific evidence on BBV prevention in 
prison settings is limited. Injecting drug use in prison 
bears the highest risk of transmission of BBVs, due to the 
re-use of contaminated injecting equipment. However, 
there are additional risks for BBV transmission in prison 
settings which can be prevented. A comprehensive 
package of combination prevention, including the following 
interventions, may be considered: 
Opioid substitution treatment: Studies consistently 
show that while patients are in prison, being on opioid 
substitution treatment (OST) reduces opioid use, injecting 
and the sharing of injecting equipment. For those who had 
been on OST before imprisonment, prison OST provides 
treatment continuity, whereas disruption of the treatment, 
especially due to brief periods of imprisonment, has 
been associated with significantly increased risk of HCV 
seroconversion. After release, those who had received OST 
while in custody are more likely to continue treatment, and 
they face a lower risk of drug-related death.  
Provision of clean drug injecting equipment: Although 
the evidence base is very limited, studies suggest that 
the successful implementation of needle and syringe 
programmes in prison is possible and may lead — as part 
of a more comprehensive response — to a reduction of BBV 
transmission among incarcerated people who inject drugs. 
Models for syringe distribution primarily include hand-to-
hand exchange, managed by healthcare workers or other 
responsible staff, and vending machines installed in more 
discrete areas within the prison. In all models, participants 
need to enrol in the programme to be able to access 
syringes. Confidentiality and individual needs (e.g. frequency 
of injection, number of syringes per day) must to be taken 
into account when designing such programmes.
Condoms and lubricant: The evidence suggests that 
provision of condoms and the implementation of behavioural 
interventions may promote safer sex behaviours in prison 
settings. These findings are consistent with the evidence 
derived from community settings. In some EU/EEA countries 
the existing regulations prohibiting sexual activities in prison 
settings or incorrect assumptions about sexual activity in 
prison prevent the implementation of condom distribution 
programmes. However, when feasible, condom distribution 
programmes can be implemented through the installation of 
vending machines or via hand-to-hand distribution mediated 
by healthcare workers or other staff.  
Safe tattooing and body piercing: Tattooing and piercing, 
when performed with non-sterile equipment, may result in 
the spread of BBVs among tattoo and piercing recipients. 
Safe tattooing and piercing initiatives run by prison health 
services are in place in several European countries, but 
no effectiveness data is available on the impact of these 
measures on BBV transmission. Still, the acceptability is 
reportedly high among people in prison.  
Pre-and post-exposure prophylaxis for HIV: Timely post-
exposure prophylaxis (PEP) is an effective measure to 
reduce the risk of infection after exposure to HIV. It is 
advisable for this measure to be available to all people in 
prison, including, but not limited to, people in detention, 
in accordance with applicable national and international 
guidelines. Pre-exposure prophylaxis (PrEP) has recently 
been recognised as an additional effective measure to 
prevent HIV transmission, as part of a comprehensive 
package of measures.
Other interventions: Sharing of personal items such as 
razors and toothbrushes may also be considered as a 
potential source of BBV transmission, and prison authorities 
could consider providing such items (e.g. toothbrushes, 
razors) in different colours to increase ease of identification. 
Provision of disinfectants for the cleaning of personal items 
could also be considered. However, this measure may entail 
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some risk of self-harm and will need to be accompanied by 
education on their use. It is not advisable to recommend 
the use of disinfectants, including bleach, to clean needles 
and injecting equipment in prison settings. National (or 
international) guidelines providing recommendations on the 
above-listed prevention measures in community settings 
should be applied to the same standards in prison settings. 
Further important elements of combination prevention are 
testing and vaccination, as well as treatment of infections to 
reduce the pool of people in prison who carry BBVs.
Testing for BBVs
Considering the high prevalence of infection in the prison 
population and the availability of effective prevention and 
control measures, it is advisable to actively offer testing for 
HBV, HCV and HIV to all people in prison. The active offer of 
tests will promote earlier diagnosis, allow linkage to treatment 
and care, identify cases and will facilitate targeted measures 
to reduce onward transmission in the prison setting and 
after release. The body of evidence suggests that provider-
initiated strategies yield a higher uptake than client-initiated 
strategies. The available evidence indicates that health 
promotion and peer-education directed towards people in 
detention are effective in increasing testing uptake in prison 
settings. As a foundational principle for BBV prevention in 
prison, the consent of the individual is a requirement for any 
testing service provided in the prison setting. When designing 
and implementing prison testing services, it is essential to 
guarantee the individual’s right to refuse testing for BBVs.
HBV vaccination
In view of the high prevalence of HBV infection among people 
in prisons, and based on available evidence regarding the 
implementation of HBV vaccination in prison settings, as well 
as on its effectiveness in the community, it is advisable to 
offer HBV vaccination to people in prison. The offer of HBV 
vaccination at entrance to all individuals with no/unknown 
vaccination history and/or negative serology is consistent 
with the general principle of disease prevention, seeking to 
avoid further transmission within the prison setting. Evidence 
suggests that provision of HBV vaccination using the rapid or 
very rapid schedule may result in a higher vaccination course 
completion rate in prison settings.  
HIV and viral hepatitis treatment
Individuals diagnosed with HIV, HBV or HCV infection in 
prison settings should be offered appropriate treatment, in 
line with the guidelines applied in community settings. The 
evidence indicates that HIV and HCV treatment in prison 
settings is feasible. There is a strong public health rationale 
for providing prompt access to state-of-the-art viral hepatitis 
treatment and care to people in prison, among which a 
significant proportion inject drugs, or have done so in the 
past, and who, given their dynamic interaction and high 
prevalence, have been identified as key populations to be 
prioritised for HBV/HCV screening and treatment in the 
EU/EEA.
Continuity of care
Transitional care for people entering and being released 
from prison is an essential component of quality healthcare 
services for people at higher risk of acquiring a BBV infection 
and for individuals with HIV infection, chronic viral hepatitis or 
problematic drug use.
For all treatment provided in prison settings, release from 
prison and transfer within and between prison institutions 
are the most important barriers to adherence and, for HCV, 
treatment completion. Active referral to suitable community 
care services is considered the cornerstone of an effective 
linkage to care post-release, and it is widely recommended by 
existing guidelines. 
In consideration of the specificities of EU/EEA Member 
States’ national healthcare systems and arrangements with 
respect to provision of prison healthcare, active referral may 
take different approaches. Provision of an adequate supply 
of medicines to individuals on their release is implemented 
in countries such as France, Italy and Portugal, in order 
to cover the transition period until effective linkage with 
community services is established, or for the entire duration 
of the treatment, as is currently done in some countries for 
HCV treatment with interferon-free regimens. Provision of 
prescription is preferred in countries such as the United 
Kingdom, with active referral to a suitable service provider in 
the community. 
The existing body of evidence indicates that continuation and 
also uptake of OST during incarceration results in a higher 
likelihood of retention of opioid-dependent people in drug 
 The treatment of BBVs  
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dependency care after release, and in better adherence 
to HIV treatment among people who inject drugs. Active 
referral to a community-based service provider for post-
release care may be particularly important for people who 
have a history of opioid use in the light of the heightened 
mortality risk in the immediate post-release period. 
Accumulating evidence, including from the EU/EEA, attests 
to the protective effect of OST on all-cause and drug-related 
mortality after release. As a further measure to prevent 
overdose mortality, provision of a supply of naloxone at 
release has been shown to be successful in a large-scale 
programme implemented in Scotland. 
Integration of prison and community health services could 
contribute to streamlining continuity of care pathways, 
both at entry into and at release from prison. In particular, 
integrated services may result in an easier and faster referral 
system for patients and a less demanding process for the 
responsible healthcare worker.
I  Need for more research in  prison settings 
A major challenge encountered during the development of 
this guidance was the scarcity of published evidence overall 
and from the European setting in particular. An important 
conclusion is that more efforts are needed to expand the 
evidence base on effective BBV prevention and control 
interventions in prison settings. In order to fill existing 
knowledge gaps, more research, conducted in the EU/EEA, is 
needed to provide further evidence on the feasibility, (cost-) 
effectiveness and impact of interventions.
Service priorities at the different stages of detention
COMMUNITY
Entering detention
•  Health and drug use 
assessment
•  Active offer of  
BBV testing 
• HBV vaccination
During detention
•  Comprehensive 
prevention package;
•  Active offer of BBV 
testing: health promotion 
and peer education to 
increase testing uptake
•  Treatment for HIV 
infection and viral 
hepatitis
During detention
• Partnerships with 
community health
• Active referral to com-
munity health and drugs 
services
• Continuity of OST; 
naloxone take-home 
provision
Note: Services may be organised or staged differently depending on length of stay and prison health service 
organisation.
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I  Council of Europe Annual Survey on Prison Populations (SPACE)  
https://www.coe.int/en/web/prison/space 
I ECDC – www.ecdc.europa.eu
I  EMCDDA – prison website http://www.emcdda.europa.eu/topics/prison_en
I  UNODC – Publications on prison and HIV:  
http://www.unodc.org/unodc/en/hiv-aids/new/publications_prisons.html 
I  WEPHREN – Worldwide Prison Health Research and Engagement Network.  
https://wephren.tghn.org/
I  WHO Europe – Prisons and health  
http://www.euro.who.int/en/health-topics/health-determinants/prisons-and-health
Links and resources
People in prison: The population 
addressed in the guidance are 
adult individuals aged 18 years 
or older detained in prison for 
custody, remand or awaiting 
trial, and prison staff, when and 
where appropriate. 
Prison settings: The term 
prison settings refers to all 
institutions where a state holds 
adults deprived of their liberty, 
either sentenced or on pre-trial 
detention (remand), excluding 
migrant centres and police 
detention rooms, juvenile prisons 
and secure training centres for 
children and young people.
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For more on this topic 
About ECDC-EMCDDA collaboration in the prison field 
The European Centre for Disease Prevention and Control (ECDC) is an EU agency tasked with 
identifying, assessing and communicating threats to human health posed by infectious diseases. It 
supports the work of public health authorities in the EU/EEA Member States.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is an EU agency providing 
policymakers, experts and the public with a factual overview of European drug problems and a solid 
evidence base to support the drugs debate. 
The development of evidence-based public health guidance on the prevention and control of 
communicable diseases in prison settings in the EU/EEA is a joint effort by the two agencies, 
undertaken to tackle the disproportionately high prevalence of drug-related infectious diseases 
among prisoners compared with the general population.
Public health guidance documents on the prevention of communicable diseases in prison produced 
in the framework of the project cover active case-finding strategies for communicable diseases and 
prevention and control of blood-borne viruses in prison settings: 
I  European Centre for Disease Prevention and Control and European Monitoring Centre for Drugs and 
Drug Addiction (2018), Public health guidance on prevention and control of blood-borne viruses in 
prison settings, ECDC and EMCDDA, Stockholm and Lisbon, doi:10.2900/042079. 
I  European Centre for Disease Prevention and Control and European Monitoring Centre for Drugs and 
Drug Addiction (2018), Public health guidance on active case finding of communicable diseases in 
prison settings, ECDC and EMCDDA, Stockholm and Lisbon, doi:10.2900/619331.
This ‘guidance in brief’ brings together the key conclusions regarding the prevention and control 
of blood-borne viruses in prison settings, based on comprehensive reviews and analyses of the 
evidence and consultation with a scientific expert panel. For more details and a complete list of 
references, see the full guidance reports and supporting background documents, available on the 
ECDC and EMCDDA websites.
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